Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses

Michael Donkor, Jamie Choe, Danielle Marie Reid, Byron Quinn, Mark Pulse, Amalendu Ranjan, Pankaj Chaudhary, Harlan P. Jones

Research output: Contribution to journalArticlepeer-review

Abstract

Lung metastasis is a leading cause of cancer-related deaths. Here, we show that intranasal delivery of our engineered CpG-coated tumor antigen (Tag)-encapsulated nanoparticles (NPs)—nasal nano-vaccine—significantly reduced lung colonization by intravenous challenge of an extra-pulmonary tumor. Protection against tumor-cell lung colonization was linked to the induction of localized mucosal-associated effector and resident memory T cells as well as increased bronchiolar alveolar lavage-fluid IgA and serum IgG antibody responses. The nasal nano-vaccine-induced T-cell-mediated antitumor mucosal immune response was shown to increase tumor-specific production of IFN-γ and granzyme B by lung-derived CD8+ T cells. These findings demonstrate that our engineered nasal nano-vaccine has the potential to be used as a prophylactic approach prior to the seeding of tumors in the lungs, and thereby prevent overt lung metastases from existing extra pulmonary tumors.

Original languageEnglish
Article number445
JournalPharmaceutics
Volume15
Issue number2
DOIs
StatePublished - Feb 2023

Keywords

  • breast cancer
  • immune response
  • lung metastasis
  • nanoparticles
  • vaccination

Fingerprint

Dive into the research topics of 'Nasal Tumor Vaccination Protects against Lung Tumor Development by Induction of Resident Effector and Memory Anti-Tumor Immune Responses'. Together they form a unique fingerprint.

Cite this